Lindus Therapeutics
Building the next generation of pharma company.
We are in-licensing clinical-stage assets to develop through Lindus Health's integrated clinical trial operating model. Built for biotechs looking for a partner that can take a program further, faster.
82%
of Lindus sponsor trials have completed enrollment on or ahead of timeline
30+
completed trials across a broad therapeutic area spread
180
full-time employees across the US and Europe
The initiative
Leveraging our trial execution capability to build an internal asset portfolio.
Lindus Health was founded as a technology-first clinical research organization. We are extending into asset development, acquiring clinical-stage therapeutics and developing them internally using the same infrastructure that delivered 82% of our sponsor trials on or ahead of timeline.
What
In-licensing 4-5 clinical-stage therapeutic assets, typically Phase-2-ready.
Focus
Non-ultrarare chronic disease, aligned with Lindus Health's core therapeutic areas and execution capabilities.
Timeline
Targeting deal close on initial assets through 2026, with first trials launching in H1 2027.
Path forward
Develop assets internally, then assess acquisition, partnering, or later-stage development.
Funding
Initial deals and trial launches funded directly from balance sheet.
Asset identification
Proprietary data and AI models identify assets that fit Lindus' operational capabilities and therapeutic expertise.
Why Lindus
A partner that can actually execute on what you've built.
Proven in-house trial execution
A track record of delivering trials on time and on budget across 30+ completed programs. Your asset is developed by the same team that designs and executes it. No external CRO layer, no handoff, no misaligned incentives.
Faster timeline to readout
Centralized patient enrollment infrastructure combines AI-powered EHR querying, digital pre-screening, and patient concierge. This reduces screen failures and compresses enrollment timelines.
Optimized trial designs
Our technology platform and international footprint enable trial designs that aren't practical with standard biotech partners: multi-country trials, multi-indication programs, and adaptive approaches built to the asset.
Our approach
Deal structures that work for both sides.
We structure deals so that value accrues to the originating company as the program progresses. Our preference is for transaction structures that align incentives around clinical and commercial milestones rather than maximizing upfront consideration.
We are pragmatic about deal shape. Exclusive and non-exclusive licenses, territory splits, option agreements, and co-development are all on the table. We move quickly on assets that fit our therapeutic focus and operational model.
Team & advisors
Leadership with operator experience and deep scientific counsel.
Leadership
Meri Beckwith
Co-Founder, Lindus Tx
Former life sciences and healthtech venture capital investor. Co-founded Lindus after seeing CROs repeatedly fail to deliver trials on time and on budget. MSc Biology, University of Oxford.
Michael Young
Co-Founder, Lindus Tx
Previously Special Adviser to the UK Prime Minister on life sciences. Before government, advised healthcare clients at McKinsey & Company and L.E.K. Consulting.
Luke Twelves
CMO, Lindus Tx
Physician with nearly three decades of clinical and leadership experience. Former CEO of Omnes Healthcare. Trained at Oxford, Cambridge, and Durham (MBA).
Advisors
Robert Langer, ScD
Strategic Advisor
Co-founder of Moderna and 40+ biopharma companies. Institute Professor at MIT. Holds 1,400+ patents and is one of three living individuals to receive both the US National Medal of Science and the National Medal of Technology and Innovation.
Tim Garnett
Strategic Advisor
Former Chief Medical Officer and SVP at Eli Lilly (2008-2021). Oversaw regulatory affairs, patient safety, and global clinical development across the US, Europe, China, and Japan.
Alessandro Falcone
Strategic Advisor
Regional Head of JLABS Singapore for Johnson & Johnson. Previously Executive Director of Breast Cancer Oncology R&D Clinical Development Strategy at AstraZeneca, leading programs for Enhertu, Lynparza, and Imfinzi.
Get in touch